Advanced Medical Isotopes Corporation Licensed Brachytherapy Seed Patent Granted

KENNEWICK, Wash., Sept. 16, 2014 /PRNewswire/ -- Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that a patent was awarded for technology related to its brachytherapy products.  AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products.  The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue.  AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.

Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area.  According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. 

Subject to receipt of required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce an innovative yttrium-90 (Y-90) based brachytherapy product line for a range of applications for the delivery of prescribed doses of radiation to target sites.  The initial proposed products consist of:

• Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass.
• Y-90 RadioGel(TM) device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor. 
• Y-90 Polymer Topical Paste designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as "resections") to treat residual tumor cells.

Based upon its studies and analyses, AMIC believes that once approved for commercial use by the FDA and other regulators, its brachytherapy products are likely to offer numerous benefits for patients and medical professionals including: 

• High Therapeutic Index:  This implies that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
• Half Life:  Y-90 has a half-life of just 2.7 days.  Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
• No Permanent Seeds Remaining:  Current brachytherapy devices place permanent metal or glass seeds in the tumor.  AMIC's Y-90 brachytherapy seed utilizes a biodegradable, non-toxic polymer that is absorbed by the body.
• Good Safety Profile:  Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation).  X-rays or gamma radiation travels within and outside of the body.  AMIC's brachytherapy products use the yttrium-90 isotope, which is a beta-emitter.  The yttrium-90 beta-emissions travel only a short distance.
• Potential Lower Cost:  Yttrium-90 supplies are readily accessible and are relatively inexpensive.  The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.

AMIC CEO and Chairman James C. Katzaroff stated:  "We are delighted that the U.S. Patent office has awarded this patent related to our brachytherapy seed product.  We believe that there is a strong market for this product and that it offers significant benefits to patients and healthcare providers over existing brachytherapy seed products."

About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (OTCBB: ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications.  AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.  Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.  Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States.  The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans.  For more information, please visit our website, www.isotopeworld.com.

About Battelle
Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries.  Battelle operates Pacific Northwest National Laboratory in Richland, Wash., for the U.S. Department of Energy.  For more information, visit www.battelle.org.

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions.  Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated.  These risks and uncertainties include, but are not limited to, AMIC's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

SOURCE Advanced Medical Isotope Corporation